Ilya Kirgner

1.3k total citations
31 papers, 285 citations indexed

About

Ilya Kirgner is a scholar working on Hematology, Genetics and Surgery. According to data from OpenAlex, Ilya Kirgner has authored 31 papers receiving a total of 285 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Hematology, 14 papers in Genetics and 5 papers in Surgery. Recurrent topics in Ilya Kirgner's work include Myeloproliferative Neoplasms: Diagnosis and Treatment (10 papers), Acute Myeloid Leukemia Research (7 papers) and Chronic Myeloid Leukemia Treatments (7 papers). Ilya Kirgner is often cited by papers focused on Myeloproliferative Neoplasms: Diagnosis and Treatment (10 papers), Acute Myeloid Leukemia Research (7 papers) and Chronic Myeloid Leukemia Treatments (7 papers). Ilya Kirgner collaborates with scholars based in Israel, France and United States. Ilya Kirgner's co-authors include E Naparstek, Ofira Ben‐Tal, Mudi Misgav, Yair Herishanu, Amiram Eldor, Maya Koren‐Michowitz, Irit Avivi, Odit Gutwein, Katrin Herzog‐Tzarfati and Naomi Rahimi‐Levene and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cell Reports.

In The Last Decade

Ilya Kirgner

30 papers receiving 280 citations

Peers

Ilya Kirgner

HEMAT

GENET

IMMUN

Francesca Schieppati Italy

Megumi Sawada Japan

Irina Zaidman Israel

M. Kerowgan Germany

Ioannis Klonizakis Greece

Emre Tekgündüz Türkiye

Catherine Trichet France

CP Stahl United States

Guillaume Mourey France

Gislaine Borba Oliveira Brazil

Francesca Schieppati Italy

Ilya Kirgner

111 ×0.9

HEMAT

87 ×1.0

GENET

75 ×1.3

45 ×0.8

IMMUN

44 ×0.8

Citations per year, relative to Ilya Kirgner Ilya Kirgner (= 1×) peers Francesca Schieppati

Countries citing papers authored by Ilya Kirgner

Since Specialization

Citations

This map shows the geographic impact of Ilya Kirgner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ilya Kirgner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ilya Kirgner more than expected).

Fields of papers citing papers by Ilya Kirgner

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ilya Kirgner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ilya Kirgner. The network helps show where Ilya Kirgner may publish in the future.

Co-authorship network of co-authors of Ilya Kirgner

This figure shows the co-authorship network connecting the top 25 collaborators of Ilya Kirgner. A scholar is included among the top collaborators of Ilya Kirgner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ilya Kirgner. Ilya Kirgner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kiladjian, Jean‐Jacques, Alessandro M. Vannucchi, Aaron T. Gerds, et al.. (2023). Momelotinib in Myelofibrosis Patients With Thrombocytopenia: Post Hoc Analysis From Three Randomized Phase 3 Trials. HemaSphere. 7(11). e963–e963. 10 indexed citations

Feferman, Tali, David Morgenstern, Yaniv Lustig, et al.. (2021). Anti-SARS-CoV-2 antibodies elicited by COVID-19 mRNA vaccine exhibit a unique glycosylation pattern. Cell Reports. 37(11). 110114–110114. 33 indexed citations

Zur, Dinah, et al.. (2021). Bilateral Diffuse Uveal Melanocytic Proliferation in a Woman with Metastatic Scalp Squamous Cell Carcinoma Treated with Cemiplimab. Case Reports in Ophthalmology. 12(3). 961–966. 2 indexed citations

Lichter, Yael, Yishay Szekely, Ilana Goldiner, et al.. (2021). Low FXIII activity levels in intensive care unit hospitalized COVID-19 patients. Thrombosis Journal. 19(1). 79–79. 12 indexed citations

Goldvaser, Hadar, Ilya Kirgner, Avi Leader, et al.. (2021). Targeted therapies for immune thrombocytopenic purpura: a meta-analysis of randomized controlled trials. Annals of Hematology. 100(12). 2879–2887. 5 indexed citations

Varon, David, et al.. (2020). Characteristics and outcomes of adults with cytomegalovirus‐associated thrombocytopenia: a case series and literature review. British Journal of Haematology. 191(5). 863–867. 10 indexed citations

Rottenstreich, Amihai, Galit Sarig, Yona Nadir, et al.. (2020). Pregnancy and non-pregnancy related immune thrombotic thrombocytopenic purpura in women of reproductive age. Journal of Thrombosis and Thrombolysis. 51(1). 187–193. 4 indexed citations

Kirgner, Ilya, Irit Avivi, Pia Raanani, et al.. (2019). Prothrombin Complex Concentrate before Urgent Surgery in Patients Treated with Rivaroxaban and Apixaban. Acta Haematologica. 143(3). 266–271. 9 indexed citations

Tomer, Aaron, et al.. (2019). Pathogenic heparin‐induced thrombocytopenia and thrombosis (HIT) antibodies determined by rapid functional flow cytometry. European Journal Of Haematology. 103(3). 225–233. 7 indexed citations

10.

Greenbaum, Uri, Erel Joffe, Kalman Filanovsky, et al.. (2018). Can bone marrow cellularity help in predicting prognosis in myelodysplastic syndromes?. European Journal Of Haematology. 101(4). 502–507. 8 indexed citations

11.

Joffe, Erel, Dana Rosenberg, Uri Rozovski, et al.. (2017). Replacing carmustine by thiotepa and cyclophosphamide for autologous stem cell transplantation in Hodgkin’s and non-Hodgkin’s B-cell lymphoma. Bone Marrow Transplantation. 53(1). 29–33. 9 indexed citations

12.

Kirgner, Ilya, Martin Ellis, Irit Avivi, et al.. (2017). Characteristics and Outcome of Philadelphia(Ph) Negative Myeloproliferative Neoplasms(MPN) in Patients Younger Than 45 Years - a Multicenter Retrospective Study. Blood. 130. 2917–2917. 2 indexed citations

13.

Tomer, Aaron, et al.. (2017). Sensitive and Specific Functional Flow Cytometry Assay for Rapid Diagnosis of Heparin Induced Thrombocytopenia and Thrombosis (HIT). Blood. 130. 2341–2341. 1 indexed citations

14.

Mittelman, Moshe, Kalman Filanovsky, Yishai Ofran, et al.. (2016). Azacitidine-lenalidomide (ViLen) combination yields a high response rate in higher risk myelodysplastic syndromes (MDS)—ViLen-01 protocol. Annals of Hematology. 95(11). 1811–1818. 5 indexed citations

15.

Ellis, Martin, Noa Lavi, Elena Mishchenko, et al.. (2015). Ruxolitinib treatment for myelofibrosis: Efficacy and tolerability in routine practice. Leukemia Research. 39(11). 1154–1158. 7 indexed citations

16.

Rozovski, Uri, Ofira Ben‐Tal, Ilya Kirgner, Moshe Mittelman, & Mara Hareuveni. (2015). Increased Incidence of Red Blood Cell Alloantibodies in Myelodysplastic Syndrome.. PubMed. 17(10). 624–7. 6 indexed citations

17.

Sarid, Nadav, Rinat Eshel, Ilya Kirgner, et al.. (2013). JAK2 mutation: an aid in the diagnosis of occult myeloproliferative neoplasms in patients with major intraabdominal vein thrombosis and normal blood counts.. PubMed. 15(11). 698–700. 5 indexed citations

18.

Herishanu, Yair, Mudi Misgav, Ilya Kirgner, et al.. (2004). Enoxaparin can be Used Safely in Patients with Severe Thrombocytopenia due to Intensive Chemotherapy Regimens. Leukemia & lymphoma. 45(7). 1407–1411. 49 indexed citations

19.

Herishanu, Yair, et al.. (2003). Autoimmune Thrombocytopenia in Chronic Myeloid Leukemia Treated with Interferon-alpha: Differential Diagnosis and Possible Pathogenesis. Leukemia & lymphoma. 44(12). 2103–2108. 6 indexed citations

20.

Amiel, Aliza, et al.. (1999). Replication Pattern in Cancer. Cancer Genetics and Cytogenetics. 108(1). 32–37. 21 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact